Literature DB >> 12885263

Whole body pharmacokinetic models.

Ivan Nestorov1.   

Abstract

The aim of the current review is to summarise the present status of physiologically based pharmacokinetic (PBPK) modelling and its applications in drug research, and thus serve as a reference point to people interested in the methodology. The review is structured into three major sections. The first discusses the existing methodologies and techniques of PBPK model development. The second describes some of the most interesting PBPK model implementations published. The final section is devoted to a discussion of the current limitations and the possible future developments of the PBPK modelling approach. The current review is focused on papers dealing with the pharmacokinetics and/or toxicokinetics of medicinal compounds; references discussing PBPK models of environmental compounds are mentioned only if they represent considerable methodological developments or reveal interesting interpretations and/or applications.The major conclusion of the review is that, despite its significant potential, PBPK modelling has not seen the development and implementation it deserves, especially in the drug discovery, research and development processes. The main reason for this is that the successful development and implementation of a PBPK model is seen to require the investment of significant experience, effort, time and resources. Yet, a substantial body of PBPK-related research has been accumulated that can facilitate the PBPK modelling and implementation process. What is probably lagging behind is the expertise component, where the demand for appropriately qualified staff far outreaches availability.

Entities:  

Mesh:

Year:  2003        PMID: 12885263     DOI: 10.2165/00003088-200342100-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  254 in total

1.  Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs.

Authors:  P Poulin; K Schoenlein; F P Theil
Journal:  J Pharm Sci       Date:  2001-04       Impact factor: 3.534

2.  Evaluating lead bioavailability data by means of a physiologically based lead kinetic model.

Authors:  J Polák; E J O'Flaherty; G B Freeman; J D Johnson; S C Liao; P D Bergstrom
Journal:  Fundam Appl Toxicol       Date:  1996-01

Review 3.  Physiologically based pharmacokinetic models for anticancer drugs.

Authors:  H S Chen; J F Gross
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

4.  Ethnic differences in biological monitoring of several organic solvents. II. A simulation study with a physiologically based pharmacokinetic model.

Authors:  J Y Jang; P O Droz
Journal:  Int Arch Occup Environ Health       Date:  1997       Impact factor: 3.015

5.  A computer model and program for xenobiotic disposition during pregnancy.

Authors:  R H Luecke; W D Wosilait; B A Pearce; J F Young
Journal:  Comput Methods Programs Biomed       Date:  1997-07       Impact factor: 5.428

6.  Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls. II. Rates of metabolism.

Authors:  F M Parham; C J Portier
Journal:  Toxicol Appl Pharmacol       Date:  1998-07       Impact factor: 4.219

7.  Physiologically based pharmacokinetics model of primidone and its metabolites phenobarbital and phenylethylmalonamide in humans, rats, and mice.

Authors:  H A El-Masri; C J Portier
Journal:  Drug Metab Dispos       Date:  1998-06       Impact factor: 3.922

8.  Regional blood flow in conscious resting rats determined by microsphere distribution.

Authors:  I Kuwahira; N C Gonzalez; N Heisler; J Piiper
Journal:  J Appl Physiol (1985)       Date:  1993-01

9.  A distributed parameter physiologically-based pharmacokinetic model for dermal and inhalation exposure to volatile organic compounds.

Authors:  A Roy; C P Weisel; P J Lioy; P G Georgopoulos
Journal:  Risk Anal       Date:  1996-04       Impact factor: 4.000

10.  Physiologically based pharmacokinetic model for methanol in rats, monkeys, and humans.

Authors:  V L Horton; M A Higuchi; D E Rickert
Journal:  Toxicol Appl Pharmacol       Date:  1992-11       Impact factor: 4.219

View more
  58 in total

1.  Physiologically based pharmacokinetic model for composite nanodevices: effect of charge and size on in vivo disposition.

Authors:  Donald E Mager; Vidhi Mody; Chao Xu; Alan Forrest; Wojciech G Lesniak; Shraddha S Nigavekar; Muhammed T Kariapper; Leah Minc; Mohamed K Khan; Lajos P Balogh
Journal:  Pharm Res       Date:  2012-06-12       Impact factor: 4.200

2.  Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models.

Authors:  Sabine Pilari; Wilhelm Huisinga
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-07-27       Impact factor: 2.745

Review 3.  Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion.

Authors:  K Sandy Pang; Matthew R Durk
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-12-14       Impact factor: 2.745

4.  Comment on: "A Physiologically Based Pharmacokinetic Drug-Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood".

Authors:  Guo-Fu Li; Xiao Gu; Guo Yu; Shui-Yu Zhao; Qing-Shan Zheng
Journal:  Clin Pharmacokinet       Date:  2016-01       Impact factor: 6.447

5.  A novel strategy for physiologically based predictions of human pharmacokinetics.

Authors:  Hannah M Jones; Neil Parrott; Karin Jorga; Thierry Lavé
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  Structural identifiability of physiologically based pharmacokinetic models.

Authors:  James W T Yates
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-03-28       Impact factor: 2.745

7.  First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development.

Authors:  Ashley Strougo; Thomas Eissing; Ashraf Yassen; Stefan Willmann; Meindert Danhof; Jan Freijer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-02-05       Impact factor: 2.745

Review 8.  Lipid-associated oral delivery: Mechanisms and analysis of oral absorption enhancement.

Authors:  Oljora Rezhdo; Lauren Speciner; Rebecca Carrier
Journal:  J Control Release       Date:  2016-08-09       Impact factor: 9.776

Review 9.  Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver.

Authors:  X Chu; K Korzekwa; R Elsby; K Fenner; A Galetin; Y Lai; P Matsson; A Moss; S Nagar; G R Rosania; J P F Bai; J W Polli; Y Sugiyama; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2013-04-10       Impact factor: 6.875

10.  A physiologically-based recirculatory meta-model for nasal fentanyl in man.

Authors:  Richard N Upton; David J R Foster; Lona L Christrup; Ola Dale; Kristin Moksnes; Lars Popper
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-08-19       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.